LUCENTIS, generically known as ranibizumab, is a prescription medication primarily used in the treatment of age-related macular degeneration (AMD), a leading cause of vision loss in older adults. It is also indicated for the treatment of macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy in patients with diabetic macular edema. LUCENTIS is a type of drug known as a monoclonal antibody, specifically designed to inhibit vascular endothelial growth factor A (VEGF-A), a protein that plays a critical role in the formation of new blood vessels (angiogenesis) and the leakage from blood vessels, which can lead to vision loss in these conditions. Administered via injection directly into the eye by a healthcare professional, LUCENTIS works by blocking the pathways that lead to vascular leakage and abnormal blood vessel growth, thereby helping to slow the progression of the disease and in some cases, improve vision.